BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Partner of crime boss Steven Lyons arrested in Dubai - 2Online business Stages for Little Retailers
- 3Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7
- 4This Overlooked Predator Is Running Out of Time—Why Conservationists Are Racing to Save the Striped Hyena
- 5Independence from the rat race for Recent college grads: Systems and Tips
- Well known Worldwide Caf\u00e9s to Experience
- Surf Spot Mechanics: Bells Beach
- Polls open in tense Uganda election amid widespread delays
- 5 Worldwide Road Food varieties You Should Attempt
- German Winemakers Rewrite The Rules Of Riesling In A Warming World
- Go on A Careful spending plan: Modest Objections for Your List of must-dos
- The Way to Monetary Freedom: A Viable Aide
- UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
